表紙
市場調查報告書

全球糖尿病治療藥市場 2023年

Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes

出版商 GlobalData 商品編碼 576588
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
全球糖尿病治療藥市場 2023年 Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes
出版日期: 2017年09月13日內容資訊: 英文 137 Pages
簡介

本報告提供糖尿病治療藥臨床實驗、開發趨勢相關分析,全球糖尿病市場收益,預測成為暢銷藥的新化合物、新藥,主要的化合物的市場佔有率變動分析,主要企業的市場佔有率分析,及主要的契約分析等相關彙整。

第1章 目錄

第2章 簡介

  • 概要
  • 糖尿病的分類
  • 症狀
  • 診斷標準
  • 病因
  • 病理學
  • 流行病學
  • 合併症、併發症
  • 治療藥

第3章 主要上市藥

  • 概要
  • 長效型胰島素治療藥
  • 速效型胰島素治療藥
  • GLP-1受體促效劑
  • DPP-4抑制劑
  • SGLT-2抑制劑
  • 組合治療藥
  • 未滿足需求
  • 結論

第4章 開發平台形勢的評估

  • 概要
  • 開發平台開發形勢
  • 開發平台的分子標的
  • 臨床試驗形勢
  • 主要的開發中產品的評估

第5章 多方案的市場預測

  • 整體市場規模
  • 學名藥的普及
  • 收益預測:各分子標的

第6章 企業分析、定位

  • 收益、市場佔有率分析:各企業
  • 企業形勢
  • 上市藥、開發平台的組合分析

第7章 策略上檢討事項

  • 授權契約
  • 共同開發契約

第8章 附錄

圖表一覽

目錄
Product Code: GBIHC455MR

Executive Summary

Diabetes mellitus (DM) is a generalized term used to define multiple diseases with different etiologies that are characterized by chronic hyperglycemia (high blood glucose levels) resulting from insufficient synthesis, secretion or signaling of insulin - a hormone produced by the pancreas. The main role of insulin is to facilitate the absorption of glucose into skeletal muscle and fat cells following food digestion, which provides these cells with a source of energy for metabolism, and also reduces the concentration of glucose in the blood. Insulin signaling also has important roles in many processes including growth, development and controlling inflammation.

The DM market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter 2 (SGLT-2) inhibitors. Increased market diversification is expected to continue throughout the forecast period due to patent expiries for major insulin products and increased uptake of non-insulin drugs.

Incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for more than 90% of all DM cases, is growing rapidly on a global scale. The US is expected to experience the greatest rise in T2DM prevalence, and incidence rates are also expected to increase to about 4% by 2023. Several factors are driving the increase of T2DM, with aging population and the prevalence of highly calorific diets being some of the key drivers.

In 2016, the top five products, all of which are insulin products, commanded almost half of the market by sales. By 2023, the top 10 products are expected to occupy more than 40% of the market share, many of which will be non-insulin products.

Competition will intensify over the forecast period as more companies enter the DM market space. However, Novo Nordisk, which is currently the leading player in terms of market share, is expected to maintain its position throughout the forecast period. Despite declining revenues for high-grossing products such as Levemir (insulin detemir), more recent market additions such as Tresiba (insulin degludec), as well as the upcoming pipeline products such as semaglutide and oral semaglutide are expected to more than compensate.

The report "Global Diabetes Drugs Market to 2023 - A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes" comprehensively reviews the strategies of key players in the DM market, and provides market share forecasts. Pipeline and marketed products are analyzed in detail, along with the impact that products expected to come to market between 2016 and 2023 will have on existing established products. Licensing and co-marketing deals in DM are analyzed by region and value.

Companies mentioned in this report: Sanofi, Novo Nordisk, Eli Lilly, Merck and Co, Novartis, Boehringer Ingelheim, Johnson and Johnson, AstraZeneca.

Scope

  • Global revenue from the DM market between 2016 and 2023
  • Novel compounds and new drugs achieving blockbuster status by 2023
  • Analysis of market share changes for leading compounds by 2023
  • Analysis of leading companies by market share
  • Analysis of deals conducted during the 2006-2017 period

Reasons to buy

  • Understand the current treatment landscape, with profile assessments of key marketed products and a focus on historical and forecast sales patterns.
  • Gain insight into a highly diversifying market for DM products, and the factors behind the significant changes projected in market share between key compounds.
  • Analyze the DM pipeline through a comprehensive review of products, segmented by stage of development, molecule type and molecular target - as well as detailed profile assessments and multi-scenario revenue projections for the most promising late-stage pipeline candidates.
  • Consider market opportunities and potential risks associated with attempting to bring pipeline products to market by examining trends in clinical trial size, duration and failure rate by stage of development, key indication, molecule type and molecular target.
  • Predict growth in market size, with multi-scenario forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify the leading companies in the DM market and understand the factors that will influence growth and market share with profile assessments of key companies, including multi-scenario revenue projections.
  • Identify commercial opportunities in the DM deals landscape by analyzing trends in licensing and co-development deals.

1 Table of Contents

1 Table of Contents 4

  • 1.1 List of Tables 6
  • 1.2 List of Figures 7

2 Introduction 10

  • 2.1 Overview 10
  • 2.2 Classification of Diabetes 10
  • 2.3 Symptoms 11
  • 2.4 Diagnostic Criteria 11
  • 2.5 Etiology 12
    • 2.5.1 T1DM 12
    • 2.5.2 T2DM 13
  • 2.6 Pathophysiology 14
    • 2.6.1 Physiology of Glucose Metabolism 14
    • 2.6.2 T1DM Pathophysiology 15
    • 2.6.3 T2DM Pathophysiology 16
  • 2.7 Epidemiology 17
    • 2.7.1 T1DM 18
    • 2.7.2 T2DM 19
  • 2.8 Comorbidities and Complications 20
  • 2.9 Treatments 21
    • 2.9.1 Insulin Therapy 21
    • 2.9.2 Insulin Secretagogues 22
    • 2.9.3 Thiazolidinediones 23
    • 2.9.4 Biguanides 23
    • 2.9.5 Dipeptidyl Peptidase 4 Inhibitors 23
    • 2.9.6 Glucagon-Like Peptide-1 Receptor Agonists 24
    • 2.9.7 Sodium-Glucose Co-Transporter-2 Inhibitors 24
    • 2.9.8 Amylin Analogs 24
    • 2.9.9 Combination Therapies 25
    • 2.9.10 Non-pharmacological Therapy 25

3 Key Marketed Products 27

  • 3.1 Overview 27
    • 3.1.1 Market Share of the Top Five Grossing Drugs in 2016 27
    • 3.1.2 Market Share of the Five Strongest Growing Blockbuster Drugs 28
  • 3.2 Long-Acting Insulin Therapies (Basal Insulins) 29
    • 3.2.1 Lantus (insulin glargine) - Sanofi 29
    • 3.2.2 Levemir (insulin detemir) - Novo Nordisk 31
    • 3.2.3 Tresiba (insulin degludec) - Novo Nordisk 32
    • 3.2.4 Toujeo (insulin glargine) - Sanofi 33
  • 3.3 Short-Acting Insulin Therapies (Bolus Insulins) 35
    • 3.3.1 Humalog (insulin lispro) - Eli Lilly 35
    • 3.3.2 Novolog (Insulin aspart) - Novo Nordisk 36
    • 3.3.3 Apidra (insulin glulisine) - Sanofi 38
  • 3.4 GLP-1 Receptor Agonists 39
    • 3.4.1 Victoza (liraglutide) - Novo Nordisk 39
    • 3.4.2 Trulicity (dulaglutide) - Eli Lilly 41
  • 3.5 DPP-4 Inhibitors 42
    • 3.5.1 Januvia (sitagliptin) - Merck and Co 42
    • 3.5.2 Galvus (vildagliptin) - Novartis 44
    • 3.5.3 Tradjenta (linagliptin) - Boehringer Ingelheim 45
  • 3.6 SGLT-2 Inhibitors 46
    • 3.6.1 Invokana (canagliflozin) - Johnson and Johnson 46
    • 3.6.2 Jardiance (empagliflozin) - Boehringer Ingelheim 47
    • 3.6.3 Farxiga (dapagliflozin) - AstraZeneca 49
  • 3.7 Combination Therapies 50
    • 3.7.1 Soliqua 100/33 (insulin glargine and lixisenatide) - Sanofi 50
    • 3.7.2 Xultophy (insulin degludec and liraglutide) - Novo Nordisk 51
    • 3.7.3 Janumet - Merck 52
    • 3.7.4 Qtern (saxagliptin and dapagliflozin) - AstraZeneca 53
  • 3.8 Unmet Needs 54
  • 3.9 Conclusion 55

4 Pipeline Landscape Assessment 56

  • 4.1 Overview 56
  • 4.2 Pipeline Development Landscape 57
  • 4.3 Molecular Targets in the Pipeline 59
  • 4.4 Clinical Trials Landscape 61
    • 4.4.1 Clinical Trial Failure Rates 62
    • 4.4.2 Clinical Trial Duration 66
    • 4.4.3 Clinical Trial Size 69
    • 4.4.4 Aggregate Clinical Program Size 73
  • 4.5 Assessment of Key Pipeline Products 76
    • 4.5.1 Semaglutide (NN-9535) - Novo Nordisk 76
    • 4.5.2 Oral Semaglutide (OG-217SC) - Novo Nordisk 77
    • 4.5.3 ITCA 650 - Intarcia 78
    • 4.5.4 Sotagliflozin - Lexicon Pharmaceuticals and Sanofi 79
    • 4.5.5 Ertugliflozin - Merck and Co and Pfizer 81

5 Multi-scenario Market Forecast to 2023 82

  • 5.1 Overall Market Size 82
  • 5.2 Generic Penetration 86
  • 5.3 Revenue Forecast by Molecular Target 88
    • 5.3.1 Insulin Receptors 89
    • 5.3.2 GLP-1 Receptors 90
    • 5.3.3 SGLT-2 Inhibitors 90
    • 5.3.4 DPP-4 Inhibitors 91

6 Company Analysis and Positioning 93

  • 6.1 Revenue and Market Share Analysis by Company 93
    • 6.1.1 Novo Nordisk - Sales from Recently Approved and Upcoming Products to Increase Already Substantial Market Share 97
    • 6.1.2 Eli Lilly - Strong Growth to Result in Elevation to Second Place in Market 99
    • 6.1.3 Sanofi - Large Market Share Loss Due to Declining Sales of Lantus 100
    • 6.1.4 AstraZeneca - Growth in Revenue Largely Attributable to Farxiga Sales 101
    • 6.1.5 Johnson and Johnson - Continued Uptake of Invokana to Drive Market Growth 102
    • 6.1.6 Merck & Co - Patent Expiry of Januvia to Limit Growth 103
  • 6.2 Company Landscape 104
  • 6.3 Marketed and Pipeline Portfolio Analysis 104

7 Strategic Consolidations 107

  • 7.1 Licensing deals 107
    • 7.1.1 Deals by Region, Value and Year 107
    • 7.1.2 Deals by Stage of Development and Value 109
    • 7.1.3 Deals by Molecule Type and Molecular Target 109
    • 7.1.4 Licensing Deals Valued at $100m or above 111
  • 7.2 Co-Development Deals 111
    • 7.2.1 Deals by Region, Value and Year 111
    • 7.2.2 Deals by Stage of Development and Value 112
    • 7.2.3 Deals by Molecule Type and Molecular Target 113
    • 7.2.4 Co-development Deals Valued at $100m and above 115

8 Appendix 116

  • 8.1 References 116
  • 8.2 Abbreviations 123
  • 8.3 List of All Pipeline Products 125
  • 8.4 Disease List 135
  • 8.5 Methodology 135
    • 8.5.1 Coverage 135
    • 8.5.2 Secondary Research 135
    • 8.5.3 Market Size and Revenue Forecasts 136
    • 8.5.4 Pipeline Analysis 136
    • 8.5.5 Competitive Landscape 136
  • 8.6 Contact Us 137
  • 8.7 Disclaimer 137

1.1 List of Tables

  • Table 1: Diabetes Drugs Market, Global, Approved Indications for Lantus, 2017 30
  • Table 2: Diabetes Drugs Market, Global, Approved Indications for Levemir, 2017 31
  • Table 3: Diabetes Drugs Market, Global, Approved Indications for Tresiba, 2017 33
  • Table 4: Diabetes Drugs Market, Global, Approved Indications for Toujeo, 2017 34
  • Table 5: Diabetes Drugs Market, Global, Approved Indications for Humalog, 2017 35
  • Table 6: Diabetes Drugs Market, Global, Approved Indications for Novolog, 2017 37
  • Table 7: Diabetes Drugs Market, Global, Approved Indications for Apidra, 2017 38
  • Table 8: Diabetes Drugs Market, Global, Approved Indications for Victoza, 2017 40
  • Table 9: Diabetes Drugs Market, Global, Approved Indications for Trulicity, 2017 41
  • Table 10: Diabetes Drugs Market, Global, Approved Indications for Januvia, 2017 43
  • Table 11: Diabetes Drugs Market, Global, Approved Indications for Galvus, 2017 44
  • Table 12: Diabetes Drugs Market, Global, Approved Indications for Tradjenta, 2017 45
  • Table 13: Diabetes Drugs Market, Global, Approved Indications for Invokana, 2017 46
  • Table 14: Diabetes Drugs Market, Global, Approved Indications for Jardiance, 2017 48
  • Table 15: Diabetes Drugs Market, Global, Approved Indications for Farxiga, 2017 49
  • Table 16: Diabetes Drugs Market, Global, Approved Indications for Soliqua, 2017 50
  • Table 17: Diabetes Drugs Market, Global, Approved Indications for Xultophy, 2017 51
  • Table 18: Diabetes Drugs Market, Global, Approved Indications for Janumet, 2017 52
  • Table 19: Market, Global, Approved Indications for Qtern, 2017 53
  • Table 20: Diabetes Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 (Part 1) 84
  • Table 21: Diabetes Drugs Market, Global, Annual Revenue Forecast for Key Products ($m), 2016-2023 (Part 2) 85
  • Table 22: Diabetes Drugs Market, Global, Generic Usage Across Key Indications, 2017 88
  • Table 23: Diabetes Drugs Market, Global, Annual Revenue within Diabetes by Company, 2016-2023 94
  • Table 24: Abbreviations 123

1.2 List of Figures

  • Figure 1: Diabetes Drugs Market, Global, Epidemiology Patterns for T1DM, 2016-2023 18
  • Figure 2: Diabetes Drugs Market, Global, Epidemiology Patterns for T2DM, 2016-2023 19
  • Figure 3: Diabetes Drugs Market, Global, Market Share Projections for Key Established Products, 2016-2023 27
  • Figure 4: Diabetes Drugs Market, Global, Market Share Projections for Key Upcoming Products, 2016-2023 28
  • Figure 5: Diabetes Drugs Market, Global, Percentage Change in Market Share for Key Products 2016-2023 28
  • Figure 6: Diabetes Drugs Market, Global, Key Marketed Products and Approved Indications, 2017 29
  • Figure 7: Diabetes Drugs Market, Global, Annual Revenue for Lantus ($bn), 2006-2023 31
  • Figure 8: Diabetes Drugs Market, Global, Annual Revenue for Levemir ($bn), 2006-2023 32
  • Figure 9: Diabetes Drugs Market, Global, Annual Revenue for Tresiba ($bn), 2016-2023 33
  • Figure 10: Diabetes Drugs Market, Global, Annual Revenue for Toujeo ($bn), 2015-2023 35
  • Figure 11: Diabetes Drugs Market, Global, Annual Revenue for Humalog ($bn), 2006-2023 36
  • Figure 12: Diabetes Drugs Market, Global, Annual Revenue for Novolog ($bn), 2006-2023 38
  • Figure 13: Diabetes Drugs Market, Global, Annual Revenues for Apidra ($m), 2009-2023 39
  • Figure 14: Diabetes Drugs Market, Global, Annual Revenues for Victoza ($bn), 2009-2023 41
  • Figure 15: Diabetes Drugs Market, Global, Annual Revenue for Trulicity ($bn), 2014-2023 42
  • Figure 16: Diabetes Drugs Market, Global, Annual Revenue for Januvia ($bn), 2006-2023 43
  • Figure 17: Diabetes Drugs Market, Global, Annual Revenue for Galvus ($bn), 2007-2023 45
  • Figure 18: Figure 17: Diabetes Drugs Market, Global, Annual Revenues for Tradjenta ($m), 2011-2023 46
  • Figure 19: Diabetes Drugs Market, Global, Annual Revenues for Invokana ($bn), 2013-2023 47
  • Figure 20: Diabetes Drugs Market, Global, Annual Revenue for Jardiance ($bn), 2014-2023 48
  • Figure 21: Diabetes Drugs Market, Global, Annual Revenue for Farxiga ($bn), 2013-2023 50
  • Figure 22: Diabetes Drugs Market, Global, Annual Revenues for Soliqua 100/33 ($m), 2017-2023 51
  • Figure 23: Diabetes Drugs Market, Global, Annual Revenue for Xultophy ($bn), 2017-2023 52
  • Figure 24: Diabetes Drugs Market, Global, Annual Revenue for Janumet ($bn), 2007-2023 53
  • Figure 25: Diabetes Drugs Market, Global, Annual Revenue for Qtern ($m), 2017-2023 54
  • Figure 26: Diabetes Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 56
  • Figure 27: Diabetes Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2017 57
  • Figure 28: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Stage of Development, 2017 58
  • Figure 29: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecule Type, 2017 59
  • Figure 30: Diabetes Drugs Market, Global, Pipeline by Molecular Target, 2017 60
  • Figure 31: Diabetes Drugs Market, Global, T1DM and T2DM Pipeline by Molecular Target, 2017 61
  • Figure 32: Diabetes Drugs Market, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2017 62
  • Figure 33: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Indication (%), 2006-2017 63
  • Figure 34: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecule Type (%), 2006-2017 64
  • Figure 35: Diabetes Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Molecular Target (%), 2006-2017 65
  • Figure 36: Diabetes Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2017 66
  • Figure 37: Diabetes Drugs Market, Global, Clinical Trial Duration by Indication and Stage of Development (months), 2006-2017 67
  • Figure 38: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2017 68
  • Figure 39: Diabetes Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2017 69
  • Figure 40: Diabetes Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006-2017 69
  • Figure 41: Diabetes Drugs Market, Global, Clinical Trial Size by Indication and Stage of Development (participants), 2006-2017 70
  • Figure 42: Diabetes Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006-2017 71
  • Figure 43: Diabetes Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (Participants), 2006-2017 72
  • Figure 44: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Stage of Development, 2006-2017 73
  • Figure 45: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Indication and Stage of Development (participants), 2006-2017 74
  • Figure 46: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2017 75
  • Figure 47: Diabetes Drugs Market, Global, Aggregate Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2017 76
  • Figure 48: Diabetes Drugs Market, Global, Revenue Forecast for Semaglutide (NN-9535) ($bn), 2017-2023 77
  • Figure 49: Diabetes Drugs Market, Global, Revenue Forecast for Oral Semaglutide (OG-217SC) ($bn), 2020-2023 78
  • Figure 50: Diabetes Drugs Market, Global, Revenue Forecast for ITCA 650 ($bn), 2018-2023 79
  • Figure 51: Diabetes Drugs Market, Global, Revenue Forecast for Sotagliflozin ($bn), 2018-2023 80
  • Figure 52: Diabetes Drugs Market, Global, Revenue Forecast for Ertugliflozin ($m), 2017-2023 81
  • Figure 53: Diabetes Drugs Market, Global, Annual Revenue Forecast, 2016-2023 83
  • Figure 54: Diabetes Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2016-2023 87
  • Figure 55: Diabetes Drugs Market, Global, Annual Revenue Forecast for Insulin Receptors ($bn), 2016-2023 89
  • Figure 56: Diabetes Drugs Market, Global, Annual Revenue Forecast for GLP-1 Receptors, 2016-2023 90
  • Figure 57: Diabetes Drugs Market, Global, Annual Revenue Forecast for SGLT-2 Inhibitors, 2016-2023 91
  • Figure 58: Diabetes Drugs Market, Global, Annual Revenue Forecast for DPP-4 Inhibitors, 2016-2023 92
  • Figure 59: Diabetes Drugs Market, Global, Cluster by Growth and Market Share, 2016-2023 93
  • Figure 60: Diabetes Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023 95
  • Figure 61: Diabetes Drugs Market Global, Companies by Compound Annual Growth Rate (%), 2016-2023 96
  • Figure 62: Diabetes Drugs Market, Global, Revenue by Route of Acquisition, 2016-2023 97
  • Figure 63: Diabetes Drugs Market, Global, Novo Nordisk Annual Revenue Forecast, ($bn), 2016-2023 98
  • Figure 64: Diabetes Drugs Market, Global, Eli Lilly Annual Revenue Forecast ($bn), 2016-2023 99
  • Figure 65: Diabetes Drugs Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016-2023 100
  • Figure 66: Diabetes Drugs Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2016-2023 101
  • Figure 67: Diabetes Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2016-2023 102
  • Figure 68: Diabetes Drugs Market, Global, Merck and Co Annual Revenue Forecast ($bn), 2016-2023 103
  • Figure 69: Diabetes Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2016-2023 104
  • Figure 70: Diabetes Drugs Market, Global, Pipeline Developers by Level of Diabetes Specialization, 2016-2023 105
  • Figure 71: Diabetes Drugs Market, Global, Proportion of Total Company Revenue Attributable to Diabetes, 2016-2023 106
  • Figure 72: Diabetes Drugs Market, Licensing Deals by Region, Value and Year, 2006-2017 108
  • Figure 73: Diabetes Drugs Market, Global, Number of Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 109
  • Figure 74: Diabetes Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2017 110
  • Figure 75: Diabetes Drugs Market, Global, Licensing Deals Valued at $100m and above, 2006-2017 111
  • Figure 76: Diabetes Drugs Market, Global, Co-development Deals by Region, Value and Year, 2006-2017 112
  • Figure 77: Diabetes Drugs Market, Global, Number of Co-development Deals by Value and Stage of Development, 2006-2017 113
  • Figure 78: Diabetes Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2017 114
  • Figure 79: Diabetes Drugs Market, Global, Co-development Deals Valued at $100m and above, 2006-2017 115
  • Figure 80: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 1) 125
  • Figure 81: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 2) 126
  • Figure 82: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 3) 127
  • Figure 83: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 4) 128
  • Figure 84: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 5) 129
  • Figure 85: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 6) 130
  • Figure 86: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 7) 131
  • Figure 87: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 8) 132
  • Figure 88: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 9) 133
  • Figure 89: Diabetes Drugs Market, Global, All Pipeline Products, 2017 (Part 10) 134